피망 바카라 Lab introduces ‘IVL-GeneFluidic®’ LNP manufacturing platform at ASGCT – Aiming for global CDMO market

[by Lee, Young Sung] Inventage Lab, a drug delivery technology platform company, announced on May 14 that it will showcase its next-generation gene therapy manufacturing platform, ‘IVL-GeneFluidic®,’ based on lipid nanoparticles (LNPs), along with its research and process automation equipment, ‘HandyGene,’ at the ‘28th American Society for Gene & Cell Therapy (ASGCT) 2025.’ The company plans to present these technologies through a single booth at the conference taking place in New Orleans, USA, from May 13 to 17 (local time).

The American Society for Gene & Cell Therapy (ASGCT) is the world’s leading academic conference in the field of gene and cell therapy, attracting over 10,000 pharmaceutical and biotechnology professionals from around the world. It serves as a key 피망 바카라 for appraising the latest technological trends and advancements in next-generation treatment development.

At the conference, 피망 바카라 Lab will showcase the fully technological capabilities of its integrated LNP manufacturing platform, ‘IVL-GeneFluidic®’, for the first time in the world. The company aims to strengthen partnerships with international firms by promoting its vision of becoming a ‘Gene to GMP’ contract development and manufacturing organization (CDMO), supported by an automated system that seamlessly connects research to GMP production.

‘IVL-GeneFluidic®’ is a microfluidic-based automated platform designed for the efficient and reproducible manufacturing of mRNA and LNP formulations. This next-generation, CDMO-exclusive system simultaneously supports rapid experimental optimization, scalable production, and process validation. It is powered by the independently developed HandyGene equipment from 피망 바카라 Lab, which stands out as an integrated solution that seamlessly connects laboratory screening to large-scale GMP manufacturing in a single workflow, providing comprehensive support for the design, production, and quality control of LNP formulations.

피망 바카라 Lab is at the forefront of several large-scale national R&D projects centered on LNP technology, positioning itself as a key player in the Korean gene therapy and mRNA vaccine industries.

Notably, 피망 바카라 Lab is currently participating in the 'Development of Advanced Vaccine Raw Materials Production Technology (Development of Vaccine Production Process Technology)' project led by the Ministry of Trade, Industry and Energy, as well as the 'Establishment of a Vaccine Decentralized Production System' initiative, part of the 'Korean ARPA-H' (Advanced Research Projects Agency for Health and Medical Affairs) project led by the Ministry of Health and Welfare and the Korea Health Industry Development Institute (KHIDI).

Recently, 피망 바카라 Lab was selected for the 'Development of Pandemic Response mRNA Vaccines' national project, led by the Korea Disease Control and Prevention Agency. As part of this initiative, the company is conducting non-clinical research on vaccines for responding to COVID-19 variants and emerging variant infectious diseases. Through this project, 피망 바카라 Lab is accelerating the localization of LNP manufacturing technology for next-generation mRNA vaccines and establishing a rapid response capability.

"At this year’s ASGCT, we will present our proprietary technology and GMP-compliant automation solutions to a global audience for the first time, solidifying our position in the gene therapy CDMO market," an 피망 바카라 Lab official stated. “HandyGene is a core component of a platform that extends beyond basic research equipment, supporting both clinical and commercial production. Meanwhile, the IVL-GeneFluidic® platform represents a next-generation manufacturing technology that has attracted interest from major global pharmaceutical companies, marking a potential turning point in the global CDMO paradigm.”

“This conference holds particular significance as it marks the first global showcase of the IVL-GeneFluidic® 피망 바카라, which has recently garnered significant market attention and generated high expectations following the promising results of our oral GLP-1 treatment,” the official further commented. “We will continue to refine our 피망 바카라 technologies to demonstrate our competitiveness in the global gene therapy development market.”